Insmed Incorporated (NASDAQ:INSM) CEO Sells $479,192.80 in Stock

by · The Cerbat Gem

Insmed Incorporated (NASDAQ:INSM – Get Free Report) CEO William Lewis sold 6,830 shares of the company’s stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,412,107.84. This represents a 2.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

William Lewis also recently made the following trade(s):

  • On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50.
  • On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50.
  • On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50.
  • On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $6,419,415.00.
  • On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00.

Insmed Stock Up 3.3 %

INSM stock opened at $72.53 on Friday. The firm’s 50-day moving average is $75.49 and its two-hundred day moving average is $73.59. The company has a market capitalization of $13.19 billion, a price-to-earnings ratio of -12.97 and a beta of 1.07. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on INSM. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. UBS Group increased their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. lifted their target price on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Read Our Latest Research Report on INSM

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Elequin Capital LP bought a new stake in Insmed in the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in Insmed during the fourth quarter valued at approximately $47,000. Finally, NBC Securities Inc. bought a new stake in Insmed during the first quarter worth approximately $49,000.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Stories